Crypto Pundit Says If You Are Holding XLM, Read This
Stellar’s real-world asset ecosystem has crossed a threshold that few predicted just twelve months ago. On October 10, 2025, total RWA value distributed on the Stellar network sat at $895,744,932. By October 8, 2026, that figure had climbed to $4,015,300,556. That is a 4.4x increase in one year.
What the Data Shows
The growth is visible in the asset composition. A year ago, BENJI dominated the Stellar RWA landscape at $543,686,102, with USDC contributing $240,788,162. Those figures have grown, but they now share the leaderboard with a far wider range of assets.
By October 2026, Spiko Amundi Overnight Swap Fund (EUR) leads at $1,299,078,382. Ondo U.S. Dollar Yield follows at $537,164,588. BENJI holds $531,188,431. VuMe Bond 2030 has entered the picture at $500,000,000. USDC sits at $367,765,226. Assets like SpaceX Bond (Cometum), YLDS, EUR CoinVertible, and multiple Rivool Agriculture Notes now appear on the ledger alongside established names.
The network is not just growing in total value. It is growing in the variety of assets being tokenized and distributed on-chain.
Community Reaction
It is a legitimate observation. RWA growth reflects institutional and enterprise adoption of the network as infrastructure. Token price is driven by different market dynamics, such as retail demand, liquidity, and speculation. The two do not always move together in the short term.
The Outlook
Stellar has moved from a network with under $1B in tokenized real-world assets to one sitting above $4B in twelve months. The asset types are diversifying. The institutional names are multiplying.
Whether XLM price follows that growth remains the open question.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.
Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks
Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.


Trump promotes the "manufacturing card" again for midterm elections: Audi to invest $4 billion in a U.S. plant, plans annual production of 200,000 SUVs
Audi plans to invest 4 billion dollars to build a factory in the United States, with an annual production capacity of 200,000 SUVs, creating 4,500 jobs. The German labor union criticized the CEO's supportive attitude as "puzzling," and the final decision will be made by the Volkswagen supervisory board.

